Alexion Pharmaceuticals has presented data that advance the understanding of Paroxysmal Nocturnal Hemoglobinuria (PNH) and provide information for the medical community on the long-term management of the disease, including the progression of symptoms in untreated patients with PNH and the continued benefits of ongoing Soliris® (eculizumab) treatment regardless of transfusion history.